Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Trulicity ® (dulaglutide)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
How should other medications be administered with Trulicity® (dulaglutide)?
Consider a reduction of insulin and/or sulfonylurea dose to address the risk of hypoglycaemia. Dulaglutide delays gastric emptying and can alter the absorption of oral medications with rapid absorption or prolonged release.
UK_cFAQ_GLP022_ADMINISTRATION_WITH_OTHER_DRUGS
en-GB
Differences in the risk of hypoglycaemia from concomitant use of dulaglutide and other antidiabetics
Insulin or sulphonylurea
Patients receiving dulaglutide in combination with sulphonylurea or insulin may have an increased risk of hypoglycaemia.1
- The risk of hypoglycaemia may be lowered by a reduction in the dose of sulphonylurea or insulin.
- Blood glucose self-monitoring is usually not required with dulaglutide, but is necessary to adjust the dose of sulphonylurea or insulin, particularly when dulaglutide therapy is started and insulin is reduced. A stepwise approach to insulin dose reduction is recommended.1
SGLT2i or pioglitazone
When dulaglutide is added to an existing therapy with
- metformin and/or sodium-glucose co-transporter 2 inhibitor (SGLT2i) therapy or
- metformin and/or pioglitazone
the current dose of metformin and/or SGLT2i or pioglitazone, respectively, can be continued.1
Impact of altered gastric emptying on concomitant oral medications
Dulaglutide delays gastric emptying and has the potential to impact the rate of absorption of concomitantly administered oral medicinal products.1
In the clinical pharmacology studies including
- paracetamol
- atorvastatin
- digoxin
- the antihypertensives lisinopril and metoprolol
- warfarin
- the contraceptives norgestimate and ethinylestradiol
- metformin
dulaglutide doses up to 1.5 mg did not affect the absorption of the orally administered medicinal products tested to any clinically relevant degree.1
For the 4.5 mg dose, absence of major clinically relevant interactions was predicted by physiologically-based pharmacokinetic (PBPK) modelling simulations.1
No dose adjustment of the medicinal products as listed above is necessary when administered with dulaglutide.1
For patients receiving dulaglutide in combination with oral medicinal products with rapid gastrointestinal absorption or prolonged release, there is a potential for altered medicinal product exposure, particularly at the time of dulaglutide treatment initiation.1
References
1Trulicity [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
Date of Last Review: 13 July 2020
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com
Available Mon - Fri, 10am - 4pm, excluding Bank Holidays